

**SINGAPORE
BIOTECH INVEST**

21-22 March 2017

Singapore Exchange (SGX)

**HONG KONG
BIOTECH INVEST**

23-24 March 2017

KPMG Hong Kong

**AUSTRALIA-CHINA
BIOTECH INVEST**

27-28 March 2017

Shanghai Marriott Hotel City Centre

Race Oncology

Race Oncology is a specialty pharma company pursuing late stage drug assets overlooked by big pharma. Our first asset is a chemotherapy drug called Bisantrene, which was the subject of more than 40 phase II studies, before it was lost in a series of big pharma mergers during the 1990s. We intend to complete final clinical development and seek regulatory approval in the US for relapsed/refractory Acute Myeloid Leukemia (AML). In the meantime and commencing during 2017, we expect to start selling Bisantrene via a named patient program (NPP) in Europe.

